

Statutory Instrument 2004 No. 1031

The Medicines for Human Use (Clinical Trials) Regulations 2004

© Crown Copyright 2004

STATUTORY INSTRUMENTS

2004 No. 1031

MEDICINES

The Medicines for Human Use (Clinical Trials) Regulations 2004

| | |
|-------------------------------|------------------------|
| <i>Made</i> | <i>31st March 2004</i> |
| <i>Laid before Parliament</i> | <i>1st April 2004</i> |
| <i>Coming into force</i> | <i>1st May 2004</i> |

ARRANGEMENT OF REGULATIONS

PART 1

INTRODUCTORY PROVISIONS

1. Citation and commencement
2. Interpretation
3. Sponsor of a clinical trial
4. Responsibility for functions under the Directive

PART 2

ETHICS COMMITTEES

5. United Kingdom Ethics Committees Authority
6. Establishment of ethics committees
7. Recognition of ethics committees
8. Revocation of recognition
9. Constitution and operation of ethics committees

10. Other functions of the Authority

PART 3

AUTHORISATION FOR CLINICAL TRIALS AND ETHICS COMMITTEE OPINION

11. Interpretation of Part 3
12. Requirement for authorisation and ethics committee opinion
13. Supply of investigational medicinal products for the purpose of clinical trials
14. Application for ethics committee opinion
15. Ethics committee opinion
16. Review and appeal relating to ethics committee opinion
17. Request for authorisation to conduct a clinical trial
18. Authorisation procedure for clinical trials involving general medicinal products
19. Authorisation procedure for clinical trials involving medicinal products for gene therapy etc.
20. Authorisation procedure for clinical trials involving medicinal products with special characteristics
21. Clinical trials conducted in third countries
22. Amendments to clinical trial authorisation
23. Amendments by the licensing authority
24. Amendments by the sponsor
25. Modifying or adapting rejected proposals for amendment
26. Reference to the appropriate committee or the Medicines Commission
27. Conclusion of clinical trial

PART 4

GOOD CLINICAL PRACTICE AND THE CONDUCT OF CLINICAL TRIALS

28. Good clinical practice and protection of clinical trial subjects
29. Conduct of trial in accordance with clinical trial authorisation etc.
30. Urgent safety measures
31. Suspension or termination of clinical trial

PART 5

PHARMACOVIGILANCE

32. Notification of adverse events
33. Notification of suspected unexpected serious adverse reactions
34. Clinical trials conducted in third countries
35. Annual list of suspected serious adverse reactions and safety report

PART 6

MANUFACTURE AND IMPORTATION OF INVESTIGATIONAL MEDICINAL PRODUCTS

36. Requirement for authorisation to manufacture or import investigational medicinal products
37. Exemption for hospitals and health centres
38. Application for manufacturing authorisation
39. Consideration of application for manufacturing authorisation
40. Grant or refusal of manufacturing authorisation
41. Application and effect of manufacturing authorisation
42. Obligations of manufacturing authorisation holder
43. Qualified persons
44. Variation of manufacturing authorisation
45. Suspension and revocation of manufacturing authorisation

PART 7

LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS

46. Labelling

PART 8

ENFORCEMENT AND RELATED PROVISIONS

47. Application of enforcement provisions of the Act
48. Infringement notices
49. Offences
50. False or misleading information
51. Defence of due diligence
52. Penalties

PART 9

MISCELLANEOUS PROVISIONS

53. Construction of references to specified publications
54. Consequential and other amendments to enactments
55. Revocations
56. Transitional provisions

SCHEDULES

1. Conditions and principles of good clinical practice and the

protection of clinical trial subjects

2. Additional provisions relating to ethics committees
3. Particulars and documents that must accompany an application for an ethics committee opinion, a request for authorisation, a notice of amendment and a notification of the conclusion of a trial
4. Appeal against unfavourable ethics committee opinion
5. Procedural provisions relating to the refusal or amendment of, or imposition of conditions relating to, clinical trial authorisations and the suspension or termination of clinical trials
6. Particulars that must accompany an application for a manufacturing authorization
7. Standard provisions for manufacturing authorizations
8. Procedural provisions relating to proposals to grant, refuse to grant, vary, suspend or revoke manufacturing authorizations
9. Modification of the enforcement provisions of the Act subject to which those provisions are applied for the purposes of these Regulations
10. Consequential and other amendments of enactments
11. Revocations
12. Transitional provisions